id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0880-0035,FDA,FDA-2012-D-0880,Final Guidance for Industry - Assessing User Fees Under the Generic Drug User Fee Amendments of 2017,Other,Guidance,2022-05-18T04:00:00Z,2022,5,2022-05-18T04:00:00Z,,2024-11-07T00:38:54Z,,1,0,09000064850894ca
FDA-2012-D-0880-0034,FDA,FDA-2012-D-0880,Assessing User Fees Under the Generic Drug User Fee Amendments of 2017; Guidance for Industry; Availability,Notice,Notice of Availability,2022-05-18T04:00:00Z,2022,5,2022-05-18T04:00:00Z,,2022-05-18T19:49:37Z,2022-10702,0,0,090000648508897a